TOP > 外国特許検索 > NUCLEOSIDE DERIVATIVE AND USE THEREOF

NUCLEOSIDE DERIVATIVE AND USE THEREOF UPDATE 新技術説明会

外国特許コード F170009069
整理番号 (S2015-2046-N0)
掲載日 2017年5月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP077006
国際公開番号 WO 2017047594
国際出願日 平成28年9月13日(2016.9.13)
国際公開日 平成29年3月23日(2017.3.23)
優先権データ
  • 特願2015-180893 (2015.9.14) JP
発明の名称 (英語) NUCLEOSIDE DERIVATIVE AND USE THEREOF UPDATE 新技術説明会
発明の概要(英語) Provided is a nucleoside derivative represented by formula (1). (In formula (1), Y represents an unfused aromatic or heterocyclic hydrocarbon group or a fused polycyclic based hydrocarbon group, W1 represents a hydrogen atom, a hydroxyl group-protecting group, or a phosphate ester group, W2 represents a hydrogen atom, a hydroxyl group-protecting group, or a phosphate ester group, and R1, R2, and R3 each independently represent a hydrogen atom or a linear saturated hydrocarbon group having 1-4 carbon atoms.)
従来技術、競合技術の概要(英語) BACKGROUND ART
Is a nucleic acid drug, RNA and DNA is a component of the combination of 4 kinds of bases chemically synthesized pharmaceuticals, acts directly on the disease-causing gene is believed to inhibit expression thereof. Is a nucleic acid drug, using antisense DNA antisense pharmaceutical, pharmaceutical siRNA using RNA, pharmaceutical miRNA and the like. For example, the antisense method, antisense DNA complementary single-stranded mRNA corresponding by binding to a method for inhibiting the expression of protein, its mechanism of action of the pre-mRNA splicing inhibition or mRNA due to steric hindrance such as inhibition of ribosome binding to the, degradation of mRNA by RNase H is two.
DNA/RNA double-stranded RNA is RNase H chain only specifically hydrolyze enzyme, is RNase H antisense DNA/RNA if a substrate of the double-stranded, antisense DNA expression of the protein is a catalytic amount can be suppressed. Is in an antisense approach in order to establish, synthesized oligonucleotides and the target mRNA to form a stable double-stranded, that are present in vivo nuclease resistance to necessary when pressure or the like.
In addition, also in the nucleic acid drug such as siRNA or miRNA, synthesized RNA and the target mRNA to form a stable double-stranded, that is resistant to the nucleases present in the organism and the like can be similarly required.
Up oligonucleosides derivatives, benzene - synthesis of artificial nucleic acid phosphate backbone have been reported (patent document 1). In addition, sugar portion from the backbone methylene glycol nucleic acid (GNA) will also have been reported (non-patent document 1).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • GIFU UNIVERSITY
  • 発明者(英語)
  • UENO Yoshihito
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
岐阜大学産官学連携推進本部では、岐阜大学における知的財産の創出・管理・活用のマネジメントをしています。上記の特許・技術に関心のある方は、下記問い合わせ先に整理番号とともにご相談下さい。

PAGE TOP

close
close
close
close
close
close